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Objectives: To establish the role of specific, non-synonymous SNPs in the RNA polymerase b subunit (rpoB) gene
in reducing the susceptibility of Clostridium difficile to fidaxomicin and to explore the potential in vivo significance
of rpoBmutant strains.
Methods: Allelic exchange was used to introduce three different SNPs into the rpoB gene of an erythromycin-
resistant derivative (CRG20291) of C. difficile R20291. The genome sequences of the created mutants were
determined and each mutant analysed with respect to growth and sporulation rates, toxin A/B production and
cytotoxicity against Vero cells, and in competition assays. Their comparative virulence and colonization ability
was also assessed in a hamster infection model.
Results: The MIC of fidaxomicin displayed by three mutants CRG20291-TA, CRG20291-TG and CRG20291-GT was
substantially increased (.32, 8 and 2 mg/L, respectively) relative to that of the parent strain (0.25 mg/L).
Genome sequencing established that the intended mutagenic substitutions in rpoB were the only changes
present. Relative to CRG20291, all mutants had attenuated growth, were outcompeted by the parental strain,
had lower sporulation and toxin A/B production capacities, and displayed diminished cytotoxicity. In a hamster
model, virulence of all three mutants was significantly reduced compared with the progenitor strain, whereas
the degree of caecum colonization was unaltered.
Conclusions: Our study demonstrates that particular SNPs in rpoB lead to reduced fidaxomicin susceptibility.
These mutations were associated with a fitness cost in vitro and reduced virulence in vivo.
Introduction
Clostridium difficile is a spore-forming Gram-positive anaerobic
bacillus that causes gastrointestinal infections in humans.
C. difficile infection (CDI) is associated primarily with the use of
antibiotics, which disrupts the resident gut microbiota and permits
colonization.1 Over the past decade, so-called ‘hypervirulent’
strains of C. difficile have become increasingly represented among
clinical isolates, spreading throughout North America and Europe,
and have been associated with outbreaks of increased disease
severity, higher relapse rates and an expanded repertoire of antibi-
otic resistance.2,3 Such strains may have contributed to a rising
incidence of CDI—particularly in elderly patients—and an increase
in recurrent CDI.4 The US CDC recently identified CDI as an ‘urgent
threat’.3
Primary treatment of CDI often involves either metronidazole
or vancomycin, which both cause further damage to the colonic
microbiota;5 recurrent infection following treatment is seen in
20%–30% of patients.6 C. difficile is intrinsically resistant to many
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broad-spectrum antibiotics, which facilitates its spread within
the hospital environment,3 and C. difficile clinical isolates with
reduced susceptibility to metronidazole have been identified.7
Furthermore, an increased number of strains show reduced sus-
ceptibility to rifamycin antibiotics, which have been used to treat
relapsing CDI.8 Efforts to understand the nature of these suscepti-
bility changes are warranted to control the growing threat of anti-
biotic resistance.
Fidaxomicin is a macrocyclic antibiotic that exhibits potent
activity against C. difficile by inhibiting bacterial RNA synthesis.9 It
interferes with the formation of the DNA–RNA polymerase com-
plex before the initiation of transcription.10 Contrary to the bacter-
iostatic action of the macrolides and rifamycins, it is bactericidal
and has been shown to be narrow-spectrum. Only moderate activ-
ity has been reported against Staphylococcus aureus and
Enterococcus, and no activity reported against Bacteroides and
other Gram-negative bacteria found in the normal human gut
microflora.11 In clinical trials, fidaxomicin has been shown to be
non-inferior to vancomycin as an initial clinical cure for CDI, with a
dosing regimen of 200 mg twice daily for 10 days. It had minimal
side effects, was well tolerated and in addition, as it is hardly
adsorbed, led to very low concentrations in the plasma of patients,
but high concentrations in their faeces.12,13 Importantly,
fidaxomicin significantly reduces recurrences compared with
vancomycin.14
C. difficile strains with point mutations with reduced susceptibil-
ity to fidaxomicin were previously isolated using either a single-
step or multiple-passage approach (and one strain was isolated
from a patient in a clinical trial).15 The single-step approach gener-
ated mutant strains with point mutations in the gene encoding the
b subunit of RNA polymerase, rpoB, although any potential varia-
tions in other genes that may have influenced susceptibility were
not investigated at the time. Different SNPs led to replacement by
three different amino acids, which in turn led to variable fidaxomi-
cin MIC elevations (Table 1).15 As fidaxomicin had a decreased abil-
ity to inhibit transcription by these RNA polymerase mutants, RNA
polymerase target modification was suggested as the mechanism
by which C. difficile could develop resistance to fidaxomicin,15
although this requires further verification. Polymorphisms in other
genes may also be associated with reduced susceptibility to fidax-
omicin, such as marR/CD22120.16 The MarR (multiple antibiotic
resistance regulator) family of transcription factors is ubiquitous in
bacteria and archaea. Many are implicated in the regulation of an
operon encoding an efflux pump. Mutations within the operon can
lead to multiple antibiotic resistances.17 The clinical impact of
fidaxomicin MIC elevations is unknown.
This study aimed to use an allelic exchange approach to recre-
ate, in situ within rpoB, the point mutations potentially responsible
for elevated fidaxomicin MICs, but within a clean, isogenic back-
ground. The subsequent phenotypic characteristics, competitive
fitness and virulence of the isogenic mutants in the in vivo hamster
model of CDI were investigated to understand the potential clinical
significance of polymorphisms responsible for reduced C. difficile
susceptibility to fidaxomicin.
Materials and methods
Ethics
All animal procedures were carried out in accordance with the United
Kingdom Home Office Inspectorate under the Animals (Scientific
Procedures) Act 1986. All experiments were approved by the University
of Nottingham Ethics committee and carried out under licence number
40/3950.18,19
Antibiotics, bacterial strains and growth conditions
C. difficile strain CRG2029119 is a deliberately engineered erythromycin-
resistant derivative of the PCR-ribotype 027 R20291 strain isolated from a
UK outbreak.2 It was grown anaerobically at 37C in a Don Whitley worksta-
tion in brain heart infusion medium supplemented with 5 mg/mL yeast
extract and 0.1% (w/v) L-cysteine (BHIS) or in tryptone yeast (TY) broth.
C. difficile medium was supplemented with 250 mg/L D-cycloserine, 8 mg/L
cefoxitin and/or 15 mg/L thiamphenicol, when appropriate. Escherichia coli
TOP10 (Invitrogen) and E. coli CA434 were cultured aerobically at 37C in LB
broth, supplemented with 25 mg/L chloramphenicol,20 when appropriate.
Generation of C. difficile mutant strains by
allelic exchange
The desired single nucleotide changes were introduced into the C. difficile
genome using the previously described vector pMTL-YN4,21 but with a num-
ber of key differences. Plasmid pMTL-YN4 carries a functional copy of a
Clostridium sporogenes-derived pyrE gene, which can be used as a counter-
selection marker for double crossover mutants, provided the C. difficile
recipient is a pyrE mutant. However, we made use of an R20291pyrE-deriv-
ative strain (CRG20291) that was both macrolide, lincosamide, streptogra-
min (MLS) resistant and prototrophic through the genomic integration of an
erm(B) gene at the pyrE locus,19 concomitant with restoration of the pyrE
gene to WT. The C. difficile strain CRG20291 was chosen because the use of
R20291 in the Golden Syrian hamster is complicated by the susceptibility of
R20291 to clindamycin (MIC, 16 mg/L).19 Clindamycin treatment disrupts
the hamsters’ normal gut flora prior to infection with C. difficile. However,
clindamycin can persist at inhibitory levels (4–6lg/g) 11 days following
administration,22 and can affect the time from infection to colonization
and death of strains with different clindamycin MICs.23 CRG20291 has been
shown to provide more reliable results in the in vivo hamster infection
model.19
Directed mutagenesis
Directed mutagenesis was performed in the progenitor strain, C. difficile
CRG20291, to generate three rpoB SNPs (Table 1).15 An allelic exchange cas-
sette was synthesized (Biomatik) complementary to the rpoB region com-
prising 500 bp on either side of rpoBT3428A and containing the promoter
region upstream of rpoB (Figure 1). The cassette also incorporated flanking
restriction sites for SacI and Mlul. Following cleavage with the correspond-
ing restriction enzymes, DNA fragments were cloned into the knock-out
vector, pMTL-YN4,21 to give pMTL-YN4: rpoBT3428A. The construct was veri-
fied for the inclusion of the mutated region by restriction digest and
Table 1. Random mutants in rpoB conferring reduced susceptibility to
fidaxomicin10
Nucleotide change Amino acid change MIC (mg/L) of fidaxomicin
T3428A (TA) Val1143Asp .64
T3428G (TG)a Val1143Gly 16
G3427T (GT) Val1143Phe 2
aClinical isolate collected from a patient presenting with CDI recurrence
6 days after completion of fidaxomicin therapy.
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sequencing. Site-directed mutagenesis (Q5V
R
site-directed mutagenesis kit
NEB) was used to create the other two exchange vectors (pMTL-YN4:
rpoBT3428G and pMTL-YN4: rpoBG3427T). These were also verified by
Sanger sequencing.
The three verified plasmids were transformed into E. coli CA434 and
conjugated into C. difficile CRG20291.19 After conjugation, transconju-
gants were selected on BHIS thiamphenicol and purified colonies carrying
the modified rpoB gene conferring resistance were restreaked on BHIS
agar supplemented with 0.5 mg/L fidaxomicin (equivalent to 2%MIC).
Purified colonies were checked for plasmid loss, and purified DNA used for
PCR amplification of a region containing the changed nucleotide.19
Mutations were verified by Sanger sequencing.
WGS
Three clones of each mutant were verified by whole-genome sequencing,
genomic DNA concentrations were measured using the Qubit dsDNA BR
assay kit (Q32850, Thermo Fisher Scientific) and DNA integrity was assessed
using conventional gel electrophoresis. Standard fragment sequencing
libraries were prepared according to the Illumina TruSeq PCR free library
preparation kit (#FC-121-3001, Illumina). Genomic DNA (2lg) was frag-
mented to 400–600 bp using the Covaris S2 sonicator. Fragmented DNA
was purified using Agencourt AMPure XP beads (#A63881, Beckman
Coulter) at 1:1.6 DNA:bead ratio and end-repaired at 30C for 30 min. End-
repaired DNA was size-selected using AMPure XP beads at the desired frag-
ment length. Illumina sequencing Y adapters were ligated at 30C for
10 min and incubated at 70C for 5 min. Unligated adapters were removed
with a further two rounds of purification at 1:1 DNA:bead ratio. Purified
adapter-ligated DNA was quantified by qPCR (#KK4824, Kapa Biosystems,
Inc.), and libraries were pooled at equimolar concentrations. The library
pool was loaded at a final concentration of 10 pM on the MiSeq sequencer
for cluster generation and sequencing using 2%250 bp paired-end reads on
a full MiSeq run.
The genome sequences were compared with CRG20291 using the
quality-based variant detection workflow from CLC Genomics
Workbench.
In vitro testing of C. difficile parental and mutant
strains
MICs of fidaxomicin
The MICs of fidaxomicin for the parental strain and the three mutant strains
were determined by agar dilution according to CLSI standards.24 All assays
were performed in triplicate.
Phenotypic characterization
The three generated strains were characterized and compared with the
parental strain for: growth; growth in competition; sporulation rate and
capacity; toxin A/B production; and cytotoxicity. All in vitro experiments
were performed in triplicate.
Growth curves Mutant and parental strains were grown overnight, the
OD600 was standardized and a 1:10 dilution of each strain inoculated into
fresh BHIS broth. Growth was analysed using a plate reader, with measure-
ments taken every hour for 24 h.
Competition assays Mutant and parental strains were grown overnight,
the OD600 standardized to the lowest reading and a 1:100 dilution of each
strain inoculated together into BHIS broth. Samples were taken at 0, 2, 4, 6,
8, 10 and 24 h, diluted and plated onto BHIS-CC agar [BHIS supplemented
with cefoxitin (8 mg/L) and cycloserine (250 mg/L)] for total viable count
and onto BHIS-CC-FDX agar (BHIS-CC!2%MIC of fidaxomicin; 0.5 mg/L)
for mutant count. cfu/mL were calculated from the colony counts after a
24 h incubation.
Measurement of sporulation rates We analysed spore production over
a 120 h period. Sporulation rates were determined by measuring the devel-
opment of spores that formed cfu after heat shock over time.2
C. difficile strains were grown from frozen stocks on BHIS-CC agar.
Sporulation was achieved through incubation of cultures in BHIS broth in
anaerobic conditions at 37C for 5 days. Overnight cultures of C. difficile iso-
lates were used to inoculate a starter culture in BHIS broth diluted 1:100,
which was grown to an OD600 of between 0.2 and 0.5 to ensure low levels
of spores on inoculation of the main sporulation culture. The main culture
was then inoculated 1:100 with the starter culture (timepoint 0).
To measure colony formation, 500lL samples of the sporulation
medium were removed (at 0, 24, 48, 72, 96 and 120 h) from the anaerobic
chamber and heated at 65C for 30 min to kill vegetative cells, but not
spores. Samples were returned to the anaerobic chamber, serially diluted in
phosphate buffered saline and plated onto BHIS agar supplemented with
the bile salt taurocholate (0.1%, Sigma) to induce germination and
enhance recovery of C. difficile spores. Plates were incubated for 24 h before
heat-resistant cfu were enumerated. For all measurements of heat-
resistant cfu, a spo0Amutant strain, in which the master regulator of sporu-
lation has been inactivated, was included as a sporulation-negative
control.25
Measurement of toxin A/B production via ELISA Strains were grown in
TY broth, overnight cultures were subcultured 1:100 into fresh media and
supernatants of mutants and parental strains were collected at 24, 48 and
72 h. The production of toxin A/B was quantified by a standard curve using
a toxin A/B ELISA assay (Techlab TOX A/B ELISA
TM
). The standard curve was
produced using C. difficile toxin A and B standards (The Native Antigen
Company), serially diluted 1:2 from 125 to 1.95 ng/mL.
Measurement of cytotoxicity C. difficile strains were cultured in TY
broth. Overnight cultures were subcultured 1:100 into fresh media and
sampled at 0, 24, 48 and 72 h. At each timepoint, OD600 was measured,
samples centrifuged and the supernatant filter sterilized and stored at
#20C. The supernatants were serially diluted, added to confluent mono-
layers of Vero (African green monkey kidney) cells and incubated for 24 h
before scoring under a microscope. The toxin endpoint titre was the dilution
at which the Vero cells resembled a negative control (no cell rounding).
rpo promoter
rpo promoter
rpoB rpoC
SNP
Val1143Asp
(a)
(b)
SNP
Val1143Asp
Figure 1. Graphic representation of the directed mutagenesis approach
used in the study. (a) A section of the C. difficile genome. (b) The allelic
exchange plasmid. (a) Arrangement of rpoB and rpoC in the C. difficile
chromosome and the promoter that drives gene expression of rpoB and
rpoC. The dark grey rectangle represents the 1 kb exchange cassette con-
taining the nucleotide that was replaced. (b) The rpoB promoter and the
1 kb homology arms containing the SNP. Using homologous recombina-
tion, valine is turned into aspartic acid when rpoB is translated.
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In vivo testing of mutant strains
Virulence testing using a hamster infection model
In vitro findings were correlated with actual virulence and colonization
assays in vivo. Infectivity was assessed in infection assays using female
Golden Syrian hamsters, as described previously.19 Groups of eight ham-
sters were pretreated with clindamycin for 7 days prior to being challenged
with 105C. difficile spores. The primary output was survival or prolonged
survival. Hamsters were monitored for disease symptoms and general con-
dition, and euthanized when a predetermined threshold of symptom
severity and/or worsening of condition was met, according to a previously
published scoring system.26
Enumeration of caecal colonization
As a secondary assessment, the adherence properties of the mutant and
parental strains were compared by enumerating the bacteria obtained
from the caeca of infected hamsters. This was deemed to represent coloni-
zation. In brief, homogenized samples were centrifuged and the resulting
supernatant heat-treated at 65C prior to serial dilution and plating on
cycloserine–cefoxitin fructose agar. The number of colonies was counted
after 2–3 days of incubation.
Statistical methods
All statistical analysis was carried out using GraphPad Prism. One-way or
two-way ANOVA, followed by Dunnett’s multiple comparison test or Sidak’s
multiple comparison test, were used. All P values reported are multiplicity
adjusted.
Results
Generation of C. difficile mutant strains by
allelic exchange
The desired single nucleotide changes were introduced into the
C. difficile genome to create the CRG20291 derivative strains. In all
three instances, fidaxomicin-resistant colonies were obtained and
the presence of the anticipated SNP confirmed in each strain.
In CRG20291-TA, the thymine at rpoB position 3428 was changed
to adenine, substituting valine with aspartic acid (Val1143Asp).
In CRG20291-TG, the thymine at rpoB position 3428 was replaced
with guanine, substituting valine with glycine (Val1143Gly).
In CRG20291-GT, the guanine at position 3427 was replaced
with thymine, substituting valine with phenylalanine
(Val1143Phe). Sequencing confirmed that mutants did not contain
additional spontaneous genomic changes compared with the
parental strain.
In vitro testing of mutant strains
MICs
All constructed mutants had reduced susceptibility to fidaxomicin
compared with the parental strain. CRG20291-TA had the lowest
susceptibility (MIC .32 mg/L), followed by CRG20291-TG (8 mg/L)
and lastly CRG20291-GT (2 mg/L), versus the parental strain
(0.25 mg/L).
Strain phenotypic characterization
GrowthAll mutants grew differently compared with the parental
strain (Figure 2), with all three reaching lower peak OD600 values
than their progenitor. CRG20291-GT exhibited a shorter lag phase
versus the parental and the other two mutant strains. The time to
peak OD600 was shorter (11 h) for the parental strain compared
with14 h for both CRG20291-TA and CRG20291-TG. The genera-
tion time was similar between CRG20291-GT and the parental
strain, but marginally impaired in the CRG20291-TA and
CRG20291-TG mutants.
Growth in competition All three mutants were outcompeted
by the parental strain in vitro (Figure 3). This was statistically sig-
nificant for CRG20291-TA at the 10 h timepoint (P"0.03) and for
CRG20291-GT from the 6 h timepoint onwards (P values from
,0.0001 to 0.0031). Mutant CRG20291-TA showed a similar gen-
eration time and time-to-peak cfu count (10 h) to the parental
strain, but the parental strain showed an 8% higher total viable
count (P"0.03). Mutant CRG20291-TG exhibited similar growth,
generation time and time-to-peak count (both 8 h) to the paren-
tal strain. When mutant CRG20291-GT was compared with the
parental strain, the time-to-peak count was 10 h for both, but
the generation time for the mutant lagged behind that of the
parental strain (41 min, parental strain; 51 min, GT). Notably, the
mutant declined more rapidly versus the parental strain and,
again, peak viable count was 10% higher with the parental strain
(P,0.0001). The parental strain appeared to have a competitive
growth advantage over all three mutants, most notably com-
pared with CRG20291-GT.
Sporulation rate and capacity The initiation of sporulation was
delayed in all three mutants compared with the parental strain,
where no spores could, in contrast to the WT, be detected after
24 h (Figure 4). Strain CRG20291-TA showed the longest delay,
with heat-resistant cfu only becoming detectable after 72 h.
In fact, the number of spores present at all timepoints tested
remained significantly below that of the parental strain, even at
120 h. CRG20291-GT showed a reduced total sporulation capacity
versus the parental strain at 24, 96 and 120 h, and equalled it at
48 and 72 h. Strain CRG20291-TG also formed no heat-resistant
cfu at 24 h and fewer than the parental strain at 48 h, but
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Figure 2. Growth curves over 24 h for mutants CRG20291-TA (open
squares), CRG20291-TG (open triangles) and CRG20291-GT (filled trian-
gles) compared with the parental strain of C. difficile (filled circles).
Values are plotted as mean+ SD.
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produced more spores than the parental strain (albeit not statisti-
cally significant) from 72 h onwards. The majority of differences,
apart from that between CRG20291-TG and the parental strain at
72 h (P"0.0014), were not statistically significant.
Toxin A/B production In all three mutants, toxin A/B production
was attenuated compared with the parental strain at all time-
points measured (Figure 5a). For strain CRG20291-TG, the lag in
toxin A/B production was particularly evident, with no toxin
detected at 24 h. At 72 h, the difference in level of toxin A/B pro-
duction between mutant and parental strains was 74-fold for
CRG20291-TA, 18-fold for CRG20291-TG and 24-fold for
CRG20291-GT (P0.0001 for all measurements).
Cytotoxicity All three mutants showed reduced cytotoxicity
in Vero cells at all timepoints compared with the parental strain
(Figure 5b). At 48 and 72 h post-incubation, the culture
supernatant of strain CRG20291-TG demonstrated higher cyto-
toxicity than the other two mutant strains, although it was still
4-fold less cytotoxic than the parental strain’s culture
supernatant.
In vivo virulence and caecum colonization in the
hamster infection model
Virulence and colonization
All three mutant strains showed a statistically significant reduction
in virulence compared with the parental strain in the hamster infec-
tion model (P values from 0.0001 to 0.0087; Figure 6). CRG20291-
TA showed the lowest level of virulence (with a mean of 53.5 h until
clinical endpoint), followed by CRG20291-GT (mean 51.25 h) and
then CRG20291-TG (mean 40 h). The parental strain was the most
virulent, with a mean of 31.2 h until clinical endpoint. There was no
significant difference in colonization levels of hamster caecum
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between the parental and the mutant strains (Figure 7). The
mutant strains did colonize slightly less with averages of 1.20E!04
(CRG20291-TA), 8.96E!03 (CRG20291-TG) and 5.55E!03
(CRG20291-GT) cfu/mL compared with 2.34E!04 cfu/mL for the
parental strain.
Discussion
In the present study, we confirmed a link between the genotypic
changes in the RNA polymerase b subunit rpoB and reduced sus-
ceptibility of C. difficile to fidaxomicin using directed mutagenesis
in C. difficile. The created mutant strain CRG20291-TA had an MIC
of.32 mg/L, which is by far the highest resistance exhibited by the
three strains.
A random fidaxomicin mutant with the equivalent TA amino-
acid substitution that was previously isolated in the laboratory was
reported to have an MIC of .64 mg/L.15 The single clinical isolate
with reduced fidaxomicin susceptibility that has been reported has
an MIC of 16 mg/L. The deliberately created mutant strain,
CRG20291-TG, generated in the current study, has the same
amino-acid changes as the clinical isolate and an MIC of 8 mg/L.
Finally, strain CRG20291-GT, created here, has an MIC of 2 mg/L,
which is the same as a previously isolated random GT mutant.
These data show that the fidaxomicin susceptibilities of the
mutant strains generated in the present study are broadly in line
with the previously isolated random mutants of Seddon et al.15 An
in-depth phenotypic characterization comparing parental strain
and mutants revealed changes in virulence-associated traits, such
as competitive growth, sporulation and toxin production. First,
they showed altered growth over a 24 h period in vitro, and less
competitive growth fitness versus the parental strain. Sporulation
characteristics, an important feature of C. difficile that plays a sig-
nificant role in the transmission and recurrence of CDI, particularly
in a hospital setting, were also marginally affected in the mutant
strains.2 Toxin production and cytotoxicity were also reduced in
the mutants compared with the parental strain.
Furthermore, we found reduced virulence of the rpoB mutants
compared with the parental strain in the hamster infection model.
The virulence of strains CRG20291-TA and GT were most greatly
reduced (53.5 and 51.25 h, respectively, to the clinical endpoint
compared with 31.2 h for the parental strain). Interestingly,
CRG20291-GT was also most impaired in the competition assay
and, albeit not statistically significant, seemed to exhibit slightly
reduced colonization. The in vivo assessment of virulence might
suggest that C. difficile strains with reduced susceptibility to fidaxo-
micin may be less able to cause disease and would, as a conse-
quence, be less likely to persist in a clinical setting. It would be
interesting to investigate further whether these mutants produce
less toxin in vivo, which could play a role in their ability to cause dis-
ease. Additionally, it would be illuminating to investigate the spor-
ulation ability of these mutants, given the crucial role of spores in
persistence and transmission. So far, only one resistant clinical iso-
late has been characterized,27 which may indicate that such
strains are not particularly prevalent or widespread in the clinical
setting. Nevertheless, further investigations and evaluation are
required.
Despite the high faecal concentrations of fidaxomicin achieved
during therapy for CDI (.1 mg/g),9,28 the clinical relevance of
spontaneous rpoB mutants is unknown. In the case of rifamycin
resistance, studies have shown that no fitness cost is associated
with the mutation. Equally, it has been shown that these muta-
tions do persist in vivo, in the clinical setting.29 In the case of fidax-
omicin during all of these trials, there was only one report of a
strain with reduced susceptibility, which was isolated from a
relapse patient during a clinical trial.27
Interestingly, rpoB gene mutations that are clinically relevant
have been identified in other bacteria. For example, in
Mycobacterium tuberculosis, such mutations are thought to be
associated with varying fitness costs and some mutations have
been associated with altered cell wall permeability. These
M. tuberculosis mutations are a clinical concern and can even
accumulate in the latent stage of the disease.30,31 In Neisseria
meningitidis, different mutations within rpoBhave been associated
with a range of fitness costs, and it has been suggested that the
impact on virulence is such that they are only very rarely seen in
the clinical setting.32 Conversely, a study of rpoBmutations confer-
ring reduced susceptibility of C. difficile to rifamycin29 found that
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Figure 6. Time from spore infection to clinical endpoint (sign of infec-
tion) using the hamster model of infection for mutants CRG20291-TA
(open squares), CRG20291-TG (open triangles) and CRG20291-GT (filled
triangles) compared with the parental strain of C. difficile (filled circles).
Values are plotted as mean+ SD.
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Figure 7. Caecum colonization in the hamster model of infection. After
the endpoint, caecal colonization was evaluated, by plating on cycloser-
ine–cefoxitin fructose agar. The mutants CRG20291-TA (open squares),
CRG20291-TG (open triangles) and CRG20291-GT (filled triangles) were
compared with the parental strain of C. difficile (filled circles). Values are
plotted as mean+ SD.
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the majority of mutations generated in that study lacked in vitro
fitness costs. Among these was the Arg505Lys substitution, which
was as virulent as the WT, providing a possible explanation for its
dominance among rifamycin-resistant clinical isolates.
Our findings suggest that the specific rpoB mutations isolated
and analysed in this study that were responsible for fidaxomicin
resistance also impose a fitness cost. It might then be conceivable
that fidaxomicin is less likely to cause a rapid spread of resistant
isolates compared with other antibiotics that inhibit RNA polymer-
ase, such as the rifamycins. This suggestion is supported by the
paucity (just one) of fidaxomicin-resistant strains isolated from
clinical settings to date.27
Our study had a number of limitations, the primary one being
the small number of replicates in the samples. The use of OD (tur-
bidity) as a measurement of viable bacterial cell count is also a lim-
itation, as OD has been shown not to be truly congruent with viable
count,33 although our competition experiments were based on via-
ble counts. However, we do not perceive the limitations to be con-
siderable, as we assessed relative differences between the strains,
which would be disposed to the same limitations. Further work is
required to explore the frequency of these rpoB mutations in clini-
cal situations.
In conclusion, in the present study, rpoB mutations in C. difficile
strains were recreated using directed mutagenesis and shown to
confer reduced susceptibility to fidaxomicin. The mutants were
additionally shown to exhibit reduced competitive fitness in vitro
and to be less virulent in vivo compared with the parental strain.
The changes in phenotype that result from these alterations in the
primary sequence of rpoB may have consequences for the mutant
cell lines carrying these amino-acid substitutions. The reduced fit-
ness of such mutants might explain, at least in part, why so few
cases of fidaxomicin resistance have been reported in the litera-
ture so far.
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